| ID Source | ID |
|---|---|
| PubMed CID | 60976 |
| CHEMBL ID | 3560981 |
| CHEBI ID | 82556 |
| SCHEMBL ID | 432690 |
| MeSH ID | M0111053 |
| Synonym |
|---|
| methyl aphoxide |
| metapoxide |
| wln: t3ntj b1 apo&- at3ntj b1&- at3ntj b1 |
| ent 50,003 |
| metepa , |
| mapo |
| 1,1''-phosphinylidynetris(2-methyl)aziridine |
| n,n''-tris(1-methylethylene)phosphoramide |
| methaphoxide |
| phosphine oxide, tris[1-(2-methyl)aziridinyl]- |
| nsc-54054 |
| c 3172 |
| aziridine,1',1''-phosphinylidynetris[2-methyl- |
| phosphine oxide, tris(2-methyl-1-aziridinyl)- |
| 57-39-6 |
| nsc54054 |
| emt 50,003 |
| 1,1',1''-phosphoryltris(2-methylaziridine) |
| tris(methylaziridinyl)phosphine oxide |
| phosphine oxide, tris(1-(2-methyl)aziridinyl)- |
| ai3-50003 |
| tris(1-methylethylene)phosphoric triamide |
| aziridine, 1,1',1''-phosphinylidynetris(2-methyl- |
| tris(2-methylaziridinyl)phosphine oxide |
| tris(2-methylaziridin-1-yl)phosphine oxide |
| tris(1,2-propylene)phosphoramide |
| 1,1',1''-phosphinylidynetris(2-methyl)aziridine |
| einecs 200-326-5 |
| ccris 1435 |
| trimethylaziridinylphosphine oxide |
| nsc 54054 |
| brn 1345447 |
| tris(2-methyl-1-aziridinyl)phosphine oxide |
| n,n',n''-tris(1-methylethylene)phosphoramide |
| nsc-62578 |
| phosphine oxide, tris[1-(2-methylaziridinyl)]- |
| nsc62578 |
| nsc-62577 |
| nsc62577 |
| 1-bis(2-methylaziridin-1-yl)phosphoryl-2-methyl-aziridine |
| inchi=1/c9h18n3op/c1-7-4-10(7)14(13,11-5-8(11)2)12-6-9(12)3/h7-9h,4-6h2,1-3h3 |
| avuyxhyhttvprx-uhfffaoysa- |
| 1-bis(2-methylaziridin-1-yl)phosphoryl-2-methylaziridine |
| A831425 |
| 1-[bis(2-methyl-1-aziridinyl)phosphoryl]-2-methylaziridine |
| C19556 |
| dtxsid5020815 , |
| dtxcid50815 |
| NCGC00255220-01 |
| cas-57-39-6 |
| tox21_301807 |
| metapa |
| 9pb481h025 , |
| unii-9pb481h025 |
| aziridine, 1,1,1-phosphinylidynetris[2-methyl- |
| SCHEMBL432690 |
| AKOS022185046 |
| methapoxide |
| metepa [mi] |
| tris(2-methyl-1-aziridinyl)phosphine oxide [iarc] |
| CHEBI:82556 |
| tris(1-(2-methyl)aziridinyl)phosphine oxide |
| aziridine, 1,1',1''-phosphinylidynetris[2-methyl- |
| AVUYXHYHTTVPRX-UHFFFAOYSA-N |
| tris [1-(2-methyl)-aziridinyl] phosphine oxide |
| CHEMBL3560981 |
| c9h18n3op |
| mfcd00046984 |
| tris(1-[2-methyl]aziridinyl)phosphine oxide |
| Q3887699 |
| 1,1,1-phosphinylidynetris[2-methyl-aziridine |
| FT-0723372 |
| tris-1-(2-methylaziridinyl) phosphine oxide |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Although tepa, metepa, and apholate are only moderately toxic to rats by the oral route, the dermal toxicity of the first two is relatively high as compared with that of conventional insecticides." | ( TOXICITY OF METEPA TO RATS WITH NOTES ON TWO OTHER CHEMOSTERILANTS. GAINES, TB; KIMBROUGH, RD, 1964) | 0.97 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The organ primarily affected by repeated small doses of metepa is the testis; the ovaries and bone marrow are damaged only by higher dosage levels." | ( TOXICITY OF METEPA TO RATS WITH NOTES ON TWO OTHER CHEMOSTERILANTS. GAINES, TB; KIMBROUGH, RD, 1964) | 0.87 |
| Class | Description |
|---|---|
| phosphoramide | A compound in which one or more of the OH groups of phosphoric acid have been replaced with an amino or substituted amino group. The term is commonly confined to the phosphoric triamides, P(=O)(NR2)3, since replacement of one or two OH groups produces phosphoramidic acids: P(=O)(OH)(NR2)2 , P(=O)(OH)2(NR2). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 2.3515 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 6.8590 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 61.6448 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.69) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||